2026
article
OpenAlex
Jennifer L. Caswell‐Jin, Mark R. Somerfield, Muhammad Ali Khan, Gretchen Kimmick et autres
PURPOSE: To provide recommendations on use of medical therapies for patients with stage I-III hormone receptor-positive, HER2-negative breast cancer. METHODS: An Expert Panel including patient representation completed a systematic review of the evidence and formulated recommendations for practice. Eligible studies included patients …
us, fr, mx
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Shanu Modi, Rashmi K. Murthy, A. Jo Chien, Nancy U. Lin et autres
INTRODUCTION: Recent advances in HER2-directed therapies have improved outcomes for patients with HER2+ advanced/metastatic breast cancer (a/mBC), but disease progression ultimately occurs in most cases. Dual targeting of HER2 with tyrosine kinase inhibitors and antibody-drug conjugates has the potential for non-cross-resistant treatments …
us, gb
(code pays fourni par la source)
2007
article
OpenAlex
James R. Ouellette, David V. Cossman, Karen S. Sibert, Nicholas P. Mcandrew et autres
Primary and recurrent retroperitoneal tumors can involve the aortoiliac vasculature. They are often considered inoperable or incurable because of the locally advanced nature of the disease or the technical aspects involved in safely resecting the lesion. Safe resection of these lesions requires …
us
(code pays fourni par la source)